病患來源異種移植模型市場規模、佔有率和成長分析：按模型類型、腫瘤類型、服務類型、應用、最終用戶、託管類型和地區分類—2026-2033年產業預測

2024 年全球患者來源異種移植 (PDX) 市場價值為 17 億美元，預計從 2025 年的 18.9 億美元成長到 2033 年的 44.6 億美元，預測期（2026-2033 年）的複合年成長率為 11.3%。

全球患者來源異種移植（PDX）模型市場的發展動力源於對可靠臨床前平台日益成長的需求，這些平台能夠忠實地模擬患者特異性癌症的行為。這些免疫力缺乏動物模型使研究人員能夠以反映真實人體反應的方式研究動態、療效和抗藥性，從而支持精準醫療方法。隨著標靶治療的擴展，製藥和生物技術公司擴大將PDX模型納入其腫瘤藥物開發平臺，以檢驗生物標記並評估治療效果。與合約研究組織（CRO）和生物樣本庫進行聯合臨床試驗正在加速聯合治療的探索。此外，人工智慧的進步正在簡化該領域的藥物篩檢流程，改善候選化合物的選擇，並實現更高效的資源分配，從而提高從臨床前研究結果成功轉化為臨床應用的可能性。

全球患者來源異種移植模型市場按模型類型、腫瘤類型、服務類型、應用、最終用戶、宿主類型和地區進行細分。依模型類型分類，市場分為小鼠來源的PDX模型、大鼠來源的PDX模型、人源化PDX模型。依腫瘤類型分類，市場分為胃腸道腫瘤、肺癌、乳癌、婦科腫瘤、血液腫瘤、前列腺癌、惡性黑色素瘤和其他固體癌。依服務類型分類，市場分為模型建構、模型表徵、藥物療效測試、生物標記分析、冷凍保存和生物銀行以及客製化PDX服務。依應用分類，市場分為抗癌藥物開發、生物標記發現、精準醫療研究、臨床前試驗和轉化研究。依最終用戶分類，市場分為製藥公司、生技公司、學術和研究機構、合約研究組織（CRO）。依宿主類型分類，可分為免疫力缺乏小鼠模型及人源化免疫系統模型。依地區分類，可分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球患者來源異種移植模型市場的成長要素

全球病患來源異種移植（PDX）模型市場的發展動力源自於這些模型能夠忠實地再現個別腫瘤的生物學特徵和異質性，並常常能為治療反應提供意想不到的洞見。研究人員正利用PDX研究以病患特異性的方式評估治療效果，這與精準醫療的目標完美契合。這種協同效應促使生物製藥公司和學術機構將PDX研究整合到早期研發和轉化研究階段。這些模型對於識別預測性生物標記和製定個人化治療方案極為有用，從而導致對高品質PDX資源和服務的需求日益成長。最終，這些模型提高了臨床前研究結果的可靠性，並成為連結實驗室發現和臨床決策的關鍵橋樑。

全球患者來源異種移植模型市場的限制因素

營運患者來源異種移植（PDX）計畫面臨許多挑戰，需要專門的設施、熟練的人員和嚴格的品管措施，從而導致持續的高昂成本。這些成本不僅限於基礎設施，還包括維護免疫力缺乏動物群、確保動物得到充分照顧、遵守倫理和監管標準。因此，這些財務和後勤負擔可能會阻礙小規模學術機構和新興生技公司發展PDX能力。這種限制不僅影響PDX庫的規模和多樣性，還會減少能夠支持永續長期模型開發的機構數量，從而阻礙整體市場成長。

全球患者來源異種移植模型市場趨勢

全球患者來源異種移植（PDX）模型市場正呈現出顯著的成長趨勢，這主要得益於製藥公司和學術機構擴大將這些模型整合到轉化研究方案中。這種整合旨在彌合臨床前研究與臨床應用之間的差距，並提高臨床前研究結果對臨床決策的相關性。隨著標靶檢驗、生物標記發現和治療分析等方面的合作日益加強，對可互通的資料平台、標準化的模型表徵和共用生物樣本庫的需求也日益成長。這些進展有望加速候選化合物篩檢，簡化監管流程，最終提高臨床預測的準確性，並最大限度地減少不同產品組合中後期臨床試驗的失敗率。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球患者來源異種移植模型市場規模：按模型類型分類

• 基於小鼠的PDX模型
• 基於大鼠的PDX模型
• 人源化PDX模型

全球患者來源異種移植模型市場規模：依腫瘤類型分類

• 胃腸道癌症
• 肺癌
• 乳癌
• 婦科癌症
• 血癌
• 攝護腺癌
• 黑色素瘤
• 其他固體癌

全球患者來源異種移植模型市場規模：按服務類型分類

• 建立模型
• 模型表徵
• 藥物療效測試
• 生物標記分析
• 冷凍保存和生物銀行
• 客製化PDX服務

全球患者來源異種移植模型市場規模：按應用領域分類

• 抗癌藥物研發
• 生物標記發現
• 精準醫療調查
• 臨床前試驗
• 轉化研究

全球患者來源異種移植模型市場規模：依最終用戶分類

• 製藥公司
• 生技公司
• 學術研究機構
• 受託研究機構（CRO）

全球患者來源異種移植模型市場規模：按宿主類型分類

• 免疫力缺乏小鼠模型
• 人源化免疫系統模型

全球患者來源異種移植模型市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• The Jackson Laboratory
• Charles River Laboratories International, Inc.
• Crown Bioscience Inc.
• Champions Oncology, Inc.
• Inotiv, Inc.
• Taconic Biosciences, Inc.
• Hera BioLabs
• Wuxi AppTec Co., Ltd.
• Pharmatest Services Ltd.
• Oncodesign Services
• EPO Berlin-Buch GmbH
• Urosphere SAS
• Xentech
• Shanghai LIDE Biotech Co., Ltd.
• Creative Animodel LLC
• BioDuro-Sundia
• Living Tumor Laboratory
• Horizon Discovery Group plc
• Murine Trials in Europe AB
• Shanghai Model Organisms Center, Inc.

結論與建議

Global Patient-Derived Xenograft Model Market size was valued at USD 1.7 Billion in 2024 and is poised to grow from USD 1.89 Billion in 2025 to USD 4.46 Billion by 2033, growing at a CAGR of 11.3% during the forecast period (2026-2033).

The global patient-derived xenograft (PDX) model market is being driven by the increasing demand for reliable preclinical platforms that closely mimic patient-specific cancer behavior. These immunodeficient animal systems allow researchers to conduct studies on pharmacodynamics, efficacy, and resistance in a manner that reflects real human responses, supporting the precision medicine approach. As targeted therapies expand, pharmaceutical and biotech companies are increasingly integrating PDX models into their oncology development pipelines to validate biomarkers and test therapeutic impacts. Collaborations with CROs and biobanks for co-clinical trials enhance the exploration of combination treatments. Additionally, AI advancements are streamlining drug screening processes within this sector, improving candidate selection and enabling more efficient resource allocation, thus increasing the likelihood of successful transitions from preclinical findings to clinical applications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Patient-Derived Xenograft Model market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Patient-Derived Xenograft Model Market Segments Analysis

The global patient-derived xenograft model market is segmented by model type, tumor type, service type, application, end user, hosting type, and region. Based on model type, the market is segmented into Mice-Based PDX Models, Rat-Based PDX Models and Humanized PDX Models. Based on tumor type, the market is segmented into Gastrointestinal Cancer, Lung Cancer, Breast Cancer, Gynecological Cancer, Hematological Cancer, Prostate Cancer, Melanoma and Other Solid Tumors. Based on service type, the market is segmented into Model Establishment, Model Characterization, Drug Efficacy Testing, Biomarker Analysis, Cryopreservation & Biobanking and Custom PDX Services. Based on application, the market is segmented into Oncology Drug Development, Biomarker Discovery, Precision Medicine Research, Preclinical Testing and Translational Research. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutes and Contract Research Organizations (CROs). Based on hosting type, the market is segmented into Immunodeficient Mouse Models and Humanized Immune System Models. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Patient-Derived Xenograft Model Market

The Global Patient-Derived Xenograft (PDX) Model market is driven by the models' ability to closely replicate the biological characteristics and heterogeneity of individual tumors, which often leads to unexpected insights into treatment responses. Researchers utilize PDX studies to assess therapeutic efficacy in a patient-specific manner, aligning perfectly with the goals of personalized medicine. This synergy encourages both biopharma and academic entities to integrate PDX research into early and translational stages of development. The models are instrumental in identifying predictive biomarkers and customizing treatment plans, resulting in an increasing demand for high-quality PDX resources and services. Ultimately, these models enhance the reliability of preclinical results and serve as a crucial link between laboratory findings and clinical decision-making.

Restraints in the Global Patient-Derived Xenograft Model Market

The operation of patient-derived xenograft (PDX) programs is challenged by the need for specialized facilities, a skilled workforce, and stringent quality control measures, leading to significant ongoing costs. These expenses extend beyond just infrastructure; they include maintaining immunocompromised animal colonies, ensuring proper animal care, and adhering to ethical and regulatory standards. As a result, the financial and logistical pressures can deter smaller academic institutions and emerging biotechnology companies from developing PDX capabilities. This limitation not only affects the scale and diversity of repositories but also hinders overall market growth by decreasing the number of institutions capable of supporting sustainable long-term model development.

Market Trends of the Global Patient-Derived Xenograft Model Market

The Global Patient-Derived Xenograft (PDX) Model market is witnessing a notable trend driven by an increased integration of these models into translational research protocols by pharmaceutical companies and academic institutions. This integration aims to bridge the gap between preclinical studies and clinical applications, enhancing the relevance of preclinical findings for clinical decision-making. As collaboration intensifies around target validation, biomarker discovery, and therapeutic profiling, there is a growing demand for interoperable data platforms, standardized model characterization, and shared biorepositories. These advancements are poised to accelerate candidate screening and streamline regulatory processes, ultimately enhancing clinical predictability and minimizing late-stage trial failures across various portfolios.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Patient-derived Xenograft Model Market Size by Model Type & CAGR (2026-2033)

• Market Overview
• Mice-Based PDX Models
• Rat-Based PDX Models
• Humanized PDX Models

Global Patient-derived Xenograft Model Market Size by Tumor Type & CAGR (2026-2033)

• Market Overview
• Gastrointestinal Cancer
• Lung Cancer
• Breast Cancer
• Gynecological Cancer
• Hematological Cancer
• Prostate Cancer
• Melanoma
• Other Solid Tumors

Global Patient-derived Xenograft Model Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Model Establishment
• Model Characterization
• Drug Efficacy Testing
• Biomarker Analysis
• Cryopreservation & Biobanking
• Custom PDX Services

Global Patient-derived Xenograft Model Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology Drug Development
• Biomarker Discovery
• Precision Medicine Research
• Preclinical Testing
• Translational Research

Global Patient-derived Xenograft Model Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)

Global Patient-derived Xenograft Model Market Size by Hosting Type & CAGR (2026-2033)

• Market Overview
• Immunodeficient Mouse Models
• Humanized Immune System Models

Global Patient-derived Xenograft Model Market Size & CAGR (2026-2033)

• North America (Model Type, Tumor Type, Service Type, Application, End User, Hosting Type)
  • US
  • Canada
• Europe (Model Type, Tumor Type, Service Type, Application, End User, Hosting Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Model Type, Tumor Type, Service Type, Application, End User, Hosting Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Model Type, Tumor Type, Service Type, Application, End User, Hosting Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Model Type, Tumor Type, Service Type, Application, End User, Hosting Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• The Jackson Laboratory
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crown Bioscience Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Champions Oncology, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inotiv, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taconic Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hera BioLabs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi AppTec Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmatest Services Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncodesign Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EPO Berlin-Buch GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Urosphere SAS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xentech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai LIDE Biotech Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Animodel LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioDuro-Sundia
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Living Tumor Laboratory
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery Group plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Murine Trials in Europe AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Model Organisms Center, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations